Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Finding...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne...
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitorin...
As of March 10, 2026, the United States financial markets are witnessing an unprecedented explosion in Mergers and Acquisitions (M&A) that has caught even the most optimistic analysts by surprise. Driven by a historic surge in private equity confidence—now sitting at a six-year high of 86%—the deal-making
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
In a move that has sent shockwaves through the medical technology sector, Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for $180.00 per share in an all-cash transaction. The deal, valued at approximately $9.
Masimo’s 19% return over the past six months has outpaced the S&P 500 by 12.2%, and its stock price has climbed to $174.61 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Masimo has had an impressive run over the past six months as its shares have beaten the S&P 500 by 7.4%. The stock now trades at $174.58, marking a 13.4% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
In a move that signals a massive consolidation in the medical technology sector, Danaher Corporation (NYSE: DHR) announced on February 17, 2026, that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ: MASI) for approximately $9.9 billion. The all-cash deal, valued at $180 per share, represents
As of February 17, 2026, Danaher Corporation (NYSE: DHR) finds itself at a pivotal juncture in its multi-decade evolution. Once the darling of the "compounding" investment community, the Washington, D.C.-based life sciences giant has recently seen its share price retreat from 2025 highs, currently trading down approximately 11% year-to-date. This volatility follows a complex narrative: [...]
The deal will entail Danaher paying $180 per share for Masimo, reflecting about 18 times Masimo’s projected 2027 earnings before interest, taxes, depreciation, and amortization.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
The convergence of consumer technology and clinical medicine has reached a fever pitch as 2025 draws to a close. A landmark report released this December by ResearchAndMarkets.com projects that the wearable AI market will see a staggering $65 billion in incremental growth by 2030, driven almost entirely by its
